The DOI matches its Crossref record.
20 Years of Lipid Nanoparticles (SLN & NLC): Present State of Development & Industrial Applications
Open accessAbstract
In 1990, the lipid nanoparticles were invented in the laboratories, the first patent filings took place in 1991. The lipid nanoparticles were developed as alternative to traditional carriers such as polymeric nanoparticles and liposomes. After 20 years of lipid nanoparticles, the present state of development is reviewed - academic progress but also the development state of pharmaceutical products for the benefit of patients. Meanwhile many research groups are active worldwide, their results are reviewed which cover many different administration routes: dermal and mucosal, oral, intravenous/parenteral, pulmonary but also ocular. The lipid nanoparticles are also used for peptide/protein delivery, in gene therapy and various miscellaneous applications (e.g. vaccines). The questions of large scale production ability, accepted regulatory status of excipients, and - important for the public perception - lack of nanotoxicity are discussed, important pre-requisites for the use of each nanocarrier in products. Identical to the liposomes, the lipid nanoparticles entered first the cosmetic market, product examples are presented. Presently the pharmaceutical product development focuses on products for unmet needs and on niche products with lower development costs (e.g. ocular delivery), which can be realized also by smaller companies. A pharmaceutical perspective for the future is given, but also outlined the opportunities for non-pharmaceutical use, e.g. in nutraceuticals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Strategies to Address Low Drug Solubility in Discovery and Development
Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005660 · Cited by 1,570
Nanostructured lipid carriers: Promising drug delivery systems for future clinics
Beloqui, A., Solinís, M. Á., Rodríguez-Gascón, A., Almeida, A. J., & Préat, V. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.09.004 · Cited by 769
Müller, R. H., Gohla, S., & Keck, C. M. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.01.007 · Cited by 702
Solid Lipid Nanoparticles vs. Nanostructured Lipid Carriers: A Comparative Review
Viegas, C., Patrício, A. B., Prata, J. M., Nadhman, A., Chintamaneni, P. K., & Fonte, P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061593 · Cited by 524
Nanostructured Lipid Carriers: A Groundbreaking Approach for Transdermal Drug Delivery
Chauhan, I., Yasir, M., Verma, M., & Singh, A. P. (2020) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2020.021 · Cited by 518
Nanostructured Lipid Carriers for Delivery of Chemotherapeutics: A Review
Haider, M., Abdin, S. M., Kamal, L., & Orive, G. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030288 · Cited by 451
Nanostructured lipid carriers system: Recent advances in drug delivery
Iqbal, M. A., Md, S., Sahni, J. K., Baboota, S., Dang, S., & Ali, J. (2012) · Journal of Drug Targeting · doi:10.3109/1061186x.2012.716845 · Cited by 436
Drug nanocrystals in the commercial pharmaceutical development process
Möschwitzer, J. P. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.09.034 · Cited by 432
Doktorovova, S., Souto, E. B., & Silva, A. M. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.02.005 · Cited by 419
Skin cancer and new treatment perspectives: A review
Simões, M. C. F., Sousa, J. J. S., & Pais, A. A. C. C. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.11.001 · Cited by 414
Mitri, K., Shegokar, R., Gohla, S., Anselmi, C., & Müller, R. H. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.05.008 · Cited by 404
Self-citationGarcês, A., Amaral, M. H., Sousa Lobo, J. M., & Silva, A. C. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.11.023 · Cited by 396
Elmowafy, M., & Al-Sanea, M. M. (2021) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2021.07.015 · Cited by 382
Application of Solid Lipid Nanoparticles to Improve the Efficiency of Anticancer Drugs
Bayón-Cordero, L., Alkorta, I., & Arana, L. (2019) · Nanomaterials · doi:10.3390/nano9030474 · Cited by 344
Nanoparticles for drug delivery to the anterior segment of the eye
Janagam, D. R., Wu, L., & Lowe, T. L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.001 · Cited by 341
Lu, H., Zhang, S., Wang, J., & Chen, Q. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.783831 · Cited by 334
SLN and NLC for topical, dermal, and transdermal drug delivery
Souto, E. B., Baldim, I., Oliveira, W. P., Rao, R., Yadav, N., Gama, F. M., & Mahant, S. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1727883 · Cited by 328
Prasad, M., Lambe, U. P., Brar, B., Shah, I., J, M., Ranjan, K., Rao, R., Kumar, S., Mahant, S., Khurana, S. K., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.026 · Cited by 327
Cimino, C., Maurel, O. M., Musumeci, T., Bonaccorso, A., Drago, F., Souto, E. M. B., Pignatello, R., & Carbone, C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030327 · Cited by 324
Nanoscience and nanotechnologies in food industries: opportunities and research trends
Ranjan, S., Dasgupta, N., Chakraborty, A. R., Melvin Samuel, S., Ramalingam, C., Shanker, R., & Kumar, A. (2014) · Journal of Nanoparticle Research · doi:10.1007/s11051-014-2464-5 · Cited by 315
Aditya, N. P., Macedo, A. S., Doktorovova, S., Souto, E. B., Kim, S., Chang, P.-S., & Ko, S. (2014) · LWT - Food Science and Technology · doi:10.1016/j.lwt.2014.04.058 · Cited by 293
Topical and cutaneous delivery using nanosystems
Roberts, M., Mohammed, Y., Pastore, M., Namjoshi, S., Yousef, S., Alinaghi, A., Haridass, I., Abd, E., Leite-Silva, V., Benson, H., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.12.022 · Cited by 282
Lipid-Based Nanoparticles for Drug Delivery Systems
Samimi, S., Maghsoudnia, N., Eftekhari, R. B., & Dorkoosh, F. (2019) · Characterization and Biology of Nanomaterials for Drug Delivery · doi:10.1016/b978-0-12-814031-4.00003-9 · Cited by 266
Lipid-based nanocarriers for oral peptide delivery
Niu, Z., Conejos-Sánchez, I., Griffin, B. T., O’Driscoll, C. M., & Alonso, M. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.001 · Cited by 265
Review on the Scale-Up Methods for the Preparation of Solid Lipid Nanoparticles
Khairnar, S. V., Pagare, P., Thakre, A., Nambiar, A. R., Junnuthula, V., Abraham, M. C., Kolimi, P., Nyavanandi, D., & Dyawanapelly, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091886 · Cited by 263
Khan, S., Sharma, A., & Jain, V. (2023) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2023.056 · Cited by 259
Chen, L., Wang, Y., Zhang, J., Hao, L., Guo, H., Lou, H., & Zhang, D. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.12.005 · Cited by 78
Lipid nanoparticles for the posterior eye segment
Bonilla, L., Espina, M., Severino, P., Cano, A., Ettcheto, M., Camins, A., García, M. L., Souto, E. B., & Sánchez-López, E. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics14010090 · Cited by 76
Seeking better topical delivery technologies of moisturizing agents for enhanced skin moisturization
Kim, H., Kim, J. T., Barua, S., Yoo, S.-Y., Hong, S.-C., Lee, K. B., & Lee, J. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2017.1306054 · Cited by 57
Nanostructuring Lipid Carriers Using Ridolfia segetum (L.) Moris Essential Oil
Miranda, M., Cruz, M. T., Vitorino, C., & Cabral, C. (2019) · Materials Science and Engineering: C · doi:10.1016/j.msec.2019.109804 · Cited by 45
Metadata
- Authors
- H. Muller, R., Shegokar, R., & M. Keck, C.
- Venue
- Current Drug Discovery Technologies
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2011-09-01
- Volume
- 8
- Issue
- 3
- Pages
- 207-227
- ISSN
- 1570-1638 (ISSN-L)
- OpenAlex
- W2137017984
- Cited by
- 544
- References
- 0
- FWCI
- 12.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.